Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HRS-9231 in CNS MRI
NCT06731829Phase 2Not yet recruiting
- Sponsor
- Hengrui
- Start
- Dec 2024
- Primary completion
- Apr 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of HRS-9231 in Central nervous system lesion (4 arms), sponsored by Hengrui. Primary endpoint: Contrast-to-Noise Ratio at 1 day. Planned start Dec 2024; status: not yet recruiting.
02
Drugs
HRS-9231
03
Conditions
Central nervous system lesion
Beyond the preview
Go deeper on NCT06731829.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06731829.